Current situation in the development of a preventive HIV vaccine;Situación actual en el desarrollo de una vacuna preventiva frente al VIH

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue SUPPL.2, 2005, Pages 15-24

  Alcamí, José ^a   Munné, Joan Joseph ^b   Muñoz Fernández, María Ángeles ^c   Esteban, Mariano ^d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d CSIC   (Spain)

Author keywords

Aids; Antiviral immunity; HIV; Vaccine; Viral escape mechanisms

Indexed keywords

BACTERIUM VECTOR; BCG VACCINE; DNA VACCINE; EPITOPE; FREUND ADJUVANT; GENE THERAPY AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; LIVE VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT GLYCOPROTEIN GP 120; RECOMBINANT GLYCOPROTEIN GP 160; SALMONELLOSIS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; ECONOMIC ASPECT; ETHICS; GENE MUTATION; GENETIC VARIABILITY; HEALTH CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; MEDICAL RESEARCH; MUCOSA; NONHUMAN; SOCIAL ASPECT; VACCINATION; VIRAL GENE DELIVERY SYSTEM;

EID: 34548593602     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/s0213-005x(05)75157-0     Document Type: Article

References (68)

1. WHO. UNAIDS report on the global HIV/AIDS epidemic. Genève: WHO; 2003.
2. Nossal GJV. The global alliance for vaccines and immunization: a millennial challenge. Nature Immunol. 2000;1:1-7.
3. Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet. 2000;355:2061-6.
4. Nabel GJ. Challenges and opportunities for development of an AIDS vaccines. Nature. 2001;410:1002-6.
5. McMichael A, Hanke T. HIV vaccines 1983-2003. Nat Med. 2003;9:874-80.
6. Zinkernagel R, Doherty P. MHC-restricted cytotoxic T-cells: studies on the biological role of major transplantation antigens determining T-cell restriction-specificity, function and responsiveness. Adv Immunol. 1979;27:51-177.
7. Sung MH, Simon R. Genomewide conserved epitope profiles of HIV-1 predicted by biophysical properties of MHC binding peptides. J Comput Biol. 2004;11:125-45J.
8. Bandrés JA, Zolla-Pazner S. Inmunidad humoral en la infección por el VIH. En: González J, Moreno S, Rubio R, editores. Infección por el VIH 1999. Madrid: Doyma; 1999.
9. Nabel GJ, Sullivan NJ. antibodies and resistance to natural HIV infection. N Engl J Med. 2000;343:17-9.
10. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6:207-10.
11. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100:4144-9.
12. Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med. 1999;5:526-34.
13. Moore JP, Burton DR. HIV-1 neutralizing antibodies: how full is the bottle? Nat Med. 1999;5:142-4.
14. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol. 2002;2:706-13.
15. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004;5:233-6.
16. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature. 2001;410:980-7.
17. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997;278:1447-50.
18. Ogg GS, Jin X, Bonhoeffe S, Dunbar RP, Nowak MA, Monard S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;279:2103-6.
19. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-6.
20. Pitcher CJ, Quittner C, Paterson DM, Connors M, Koup RA, Maino VC, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Med. 1999;5:518-25.
21. Richman D. The challenge of immune control of immunodeficiency virus. J Clin Invest. 1999;104:677-8.
22. Metzner KJ, Jin X, Lee FV, Gettie A, Bauer DE, Di Mascio M, et al. Effects of in vivo CD8+ T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med. 2000;191:1921-31.
23. Thomson MM, Pérez-Álvarez L, Nájera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis. 2002;2:461-71.
24. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med. 2003;9:861-6.
25. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 1997;3:205-11.
26. O'Connor D, Hallen TM, Vogel TU, Jing P, DeSouza IP, Dodds E, et al. Acute phase citotoxic T lymphocyte escape is a hallmarg of simian immunodeficiency virus infection. Nature Med. 2002;8:493-9.
27. Brander C, Hartman KE, Trocha AK, Jones NG, Johnson RP, Korber B, et al. Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J Clin Invest. 1998;101:2559-66.
28. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol. 2002;3:1061-8.
29. Yang OO. CTL ontogeny and viral escape: implications for HIV-1 vaccine design. Trends Immunol. 2004;25:138-42.
30. Dell H. HIV- tailored to fit. Drug Discov Today. 2004;9:101.
31. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 2002;420:678-82.
32. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307-12.
33. Stahl-Hennig C, Steinman RM, Tenner-Racz K, Pope M, Stolte N, Mätz-Rensing K, et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science. 1999;285:1261-5.
34. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol. 1999;17:625-56.
35. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002;53:557-93.
36. Geijtenbeek TB, Kwon DS, Torensma R, Van Vliet SJ, Van Duijnhoven GC, Middel J, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000;100:587-97.
37. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002;417:95-8.
38. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992;258:1938-41.
39. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 1995;270:988-91.
40. Baba TW, Liska V, Khimani AH. Live-attenuated, multiply deleted SIV causes AIDS in infants and adult macaques. Nat Med. 1995;5:194-203.
41. Greenough TC, Sullivan L, Desrosiers RC. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med. 1999;340:236-7.
42. Sawai ET, Hamza MS, Ye M, Shaw KE, Luciw PA. Pathogenic conversion of live attenuated SIV vaccine is associated with expression of truncated. Nef J Virol. 2000;74:2038-45.
43. 6/L CD4 cell counts: A randomized controlled trial. JAMA. 2000;284:2193-202.
44. Francis DP, Gregory T, McElrath MJ. Advancing AIDSVAX to phase 3. Safety, immunogencity, and plans for phase 3. AIDS Res Hum Retroviruses. 1998;14:25-31.
45. Mascola JR, Snyder SW, Weislow OSl. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis. 1996;173:34-48.
46. Gallo RC. Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine. Proc Natl Acad Sci U S A. 1999;96:8324-6.
47. Bukawa H, Sekigawa K, Hamajima K, Fujushima J, Yamada Y, Kiyono H, et al. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nature Med. 1995;1:681-5.
48. Seth A, Ourmanov I, Schmith JE, Kuroda MJ, Lifton MA, Mickerson CE, et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol. 2000;74:2502-9.
49. Shiver JW, Fu TM, Chen L, Casimiro DR, Davis ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415:331-5.
50. Honda M, Matsuo K, Nakasone T, Okamoto Y, Yoshikazi H, Kitamura K, et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci U S A. 1995;92:10693-7.
51. Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther. 2000;7:20-3.
52. Boyer JD, Kim J, Ugen K, Cohen AD, Ahn L, Schuman K, et al. HIV-1 DNA vaccines and chemokines. Vaccine. 1999;17 Suppl 2:S53-64.
53. Barouch DH, Craiu A, Kuroda MJ, Schmitz JE, Zheng XX, Santra S, et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A. 2000;97:4192-7.
54. Gherardi MM, Ramírez JC, Esteban M. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J Gen Virol. 2003;84:1961-72.
55. Li S, Rodrigues M, Rodríguez D, Rodríguez JR, Esteban M, Palese P, et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A. 1993;90:5214-8.
56. Nitayaphan S, Brown AE. Preventive HIV vaccine development in Thailand. AIDS. 1998;S1:55-61.
57. Ready T. AIDSVAX flop leaves vaccine field unscathed. Nat Med. 2003;9:376.
58. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science. 2004;303:16.
59. McNeil JG, Johnston MI, Birx DL, Tramont EC. Policy rebuttal. HIV vaccine trial justified. Science. 2004;303:961.
60. Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis. 1999;180:290-8.
61. Hanke T, Samuel RV, Blanchard TJ, Neumank VC, Allen TM, Boyson JE, et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus ankara boost vaccination regimen. J Virol. 1999;73:7524-32.
62. Desrosiers R. Why an HIV vaccine is not currently within our grasp. XI CROI, San Francisco 2004 [abstract 109].
63. Ferrari G, Humphrey W, McElrath MJ. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A. 1997;94:396-401.
64. Verrier F, Burda S, Belshe R, Duliege AM, Excler JL, Klein M, et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. J Virol. 2000;74:10025-33.
65. Bloom BR. The highest attainable standard: ethical issues in AIDS vaccines. Science. 1998;279:186-8.
66. Boily MC, Masse BR, Desai K, Alary M, Anderson RM. Some important issues in the planning of phase III HIV vaccine efficacy trials. Vaccine. 1999;17:989-1004.
67. UNAIDS. Ethical considerations in HIV preventive vaccine research (document UNAIDS/00.07E). Genève: WHO; 2000.
68. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S, et al. The needfor a global HIV vaccine enterprise. Science. 2003;300:2036-8.